Retro Comparison of Subsidence Following Interbody Devices in Lumbar Spine

Study Purpose

The objective of this retrospective study is an investigational clinical follow-up, of patients treated with interbody fusion devices (IBFD), both expandable (EXP) and static (STC), according to their intended use and cleared labeling to understand IBFD design and technique characteristics that affect occurrence rates of subsidence. Patients treated with IBFD's (both EXP and STC) according to their intended use and cleared labeling. 1. EXP IBFD's that expand in width and height demonstrate reduced occurrence of subsidence post-operatively when compared to EXP IBFD's that expand in height only and STC IBFD's. 2. EXP IBFD's that are comprised of multi-material composition with Polyetheretherketone (PEEK) endplate contacting surfaces demonstrate reduced occurrence of subsidence on post-operative radiographs when compared to EXP and STC IBFD's that are primarily comprised of Ti with Ti endplate contacting surfaces. 3. achieve radiographic fusion at a rate consistent with the state-of-the-art. 4. achieve significant improvements in pain and function compared to baseline. 5. experience adverse events at a frequency comparable to reported rates for TLIF or PLIF surgery. 6. not demonstrate any intraoperative complications during the implant process. 7. operative approach does not correlate with increased rates of subsidence

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. The patient was treated with TLIF or PLIF surgery using the IBFD according to the cleared labeling, based on the surgeon's clinical judgment and patient-specific decision making. Based on the product labeling, the patient must: 1. Was at least 18 years of age and skeletally mature at the time of surgery. 2. Had clinical and radiological evidence of DDD of the lumbar spine. 3. Undergone treatment with the IBFD with autogenous bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone at 1 or 2 contiguous levels from L2 to S1.

Exclusion Criteria:

1. History of fusion surgery or large laminectomy at L2 to S1 prior to treatment with the IBFD(s) Spondylolisthesis unable to be reduced to grade 1 as part of the surgical procedure. 2. Surgery with the IBFD(s) at more than 2 contiguous levels. 3. Surgery with the IBFD(s) at levels outside the range of L2 to S1. 4. Treated with any bone grafting material other than autogenous or allogenic bone graft in the device(s) or surrounding disc space. 5. Any contraindications listed in the cleared product labeling. 6. Osteoporosis, Other Systemic Bone D.O. T score ≤ -1.5. 7. BMI > 40. 8. Systemic Infection. 9. H/O IV Drug Use. 10. Cancer

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05536453
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Spine and Scoliosis Research Associates
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Aaron Buckland, MD
Principal Investigator Affiliation SSRA Inc.
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Enrolling by invitation
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Degenerative Disc Disease (DDD)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of California San Francisco, San Francisco, California

Status

Address

University of California San Francisco

San Francisco, California, 94143

New York University Langone Health, New York, New York

Status

Address

New York University Langone Health

New York, New York, 10016

Carolina NeuroSurgery & Spine Associates, Charlotte, North Carolina

Status

Address

Carolina NeuroSurgery & Spine Associates

Charlotte, North Carolina, 28204

Rothman Orthopaedic Institute, Bensalem, Pennsylvania

Status

Address

Rothman Orthopaedic Institute

Bensalem, Pennsylvania, 19020